500KRW
21.26 BKRW
388.79 BKRW
18.42 M
About CELLTRIONPH
Sector
CEO
Jeong-Soo Suh
Headquarters
Cheongju
Website
Employees (FY)
909
Founded
2000
ISIN
KR7068760008
FIGI
BBG000L3WRG7
Celltrion Pharm, Inc. engages in the manufacture and sale of pharmaceuticals. Its products are categorized into the following: the group of medicine effect, biosimilars and over-the-counter (OTC) drug. The group of medicine effect includes hepatotonics, hepatotonics and anti-inflammatory drugs, antihistamine, respiratory apparatus drugs, circulatory system drug, digestives and stomachics drug, hormone and metabolic disease drugs, antibiotics and antimycotic, nutrientia and tonic, immunology, oncology, and the other drugs. The products of OTC drugs include alcetin tab, alchipil tab, anola tab, araphen tab, ascit granule, caldip tab, celltrion aceclofenac tab, celltrion atenolol tab, celltrion cefadroxil cap, celltrion diclofenac inj, celltrion domperidone tab, celltrion famotidine tab, and ceparo cap. The company was founded on November 17, 2000 and is headquartered in Cheongju, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 068760 is 90000 KRW — it has decreased by 4.36% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange CELLTRIONPH stocks are traded under the ticker 068760.
Yes, you can track CELLTRIONPH financials in yearly and quarterly reports right on TradingView.
Like other stocks, 068760 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLTRIONPH stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 909.00 employees. See our rating of the largest employees — is CELLTRIONPH on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLTRIONPH EBITDA is 55.75 B KRW, and current EBITDA margin is 14.34%. See more stats in CELLTRIONPH financial statements.